Stonepine Capital Management LLC Buys New Holdings in Keros Therapeutics, Inc. $KROS

Key Points

• Stonepine Capital Management LLC has acquired 100,000 shares of Keros Therapeutics, valued at approximately $1,019,000, making it the firm's 21st largest holding.
• Analysts have reduced price targets for Keros Therapeutics, with HC Wainwright lowering its target from $25 to $20, while Bank of America cut its rating from "buy" to "neutral" with a new target of $18.
• Keros Therapeutics reported a quarterly EPS of ($0.76), which exceeded analysts' estimates, and a revenue increase of over 49,000% compared to the same quarter last year, despite only generating $0.02 million in revenue.

Stonepine Capital Management LLC bought a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 100,000 shares of the company's stock, valued at approximately $1,019,000. Keros Therapeutics comprises about 1.0% of Stonepine Capital Management LLC's portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned 0.25% of Keros Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KROS. FNY Investment Advisers LLC acquired a new position in shares of Keros Therapeutics during the first quarter worth about $25,000. CWM LLC lifted its stake in shares of Keros Therapeutics by 10,157.7% during the first quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after purchasing an additional 2,641 shares in the last quarter. Virtus ETF Advisers LLC lifted its stake in shares of Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after purchasing an additional 1,998 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in shares of Keros Therapeutics by 207.8% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock worth $116,000 after purchasing an additional 4,976 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of Keros Therapeutics during the first quarter worth about $121,000. Institutional investors and hedge funds own 71.56% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on KROS shares. HC Wainwright reduced their price objective on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Scotiabank reduced their price objective on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research note on Monday, May 12th. Wedbush restated a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research note on Friday, May 30th. Finally, Bank of America cut Keros Therapeutics from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $32.00 to $18.00 in a research note on Tuesday, June 10th. Seven equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Keros Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $30.00.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS opened at $15.56 on Friday. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37. The firm has a market cap of $632.05 million, a price-to-earnings ratio of 50.20, a PEG ratio of 1.91 and a beta of 1.33. The stock's 50-day simple moving average is $14.04 and its 200-day simple moving average is $13.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. During the same period in the previous year, the company earned ($1.25) earnings per share. The company's revenue for the quarter was up 49002.7% compared to the same quarter last year. As a group, research analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.